(CFBI) –
-
Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds
-
Can-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compassionate Use Setting
-
Can-Fite BioPharma (CANF) Announces Namodenoson Increases Survival for the Most Severe Patients with Advanced Liver Cancer
-
Can-Fite Updates: Namodenoson Increases Survival for the Most Severe Patients with Advanced Liver Cancer
-
Can-Fite’s Partner Vetbiolix is Heading into a European Multicentric Clinical Trial with Piclidenoson for the Treatment of Pets’ Osteoarthritis
-
Can-Fite Reports Third Quarter 2022 Financial Results & Provides Clinical Update
-
Can-Fite: Positive New Data from it’s Phase III Psoriasis Study will be Presented Today at an Industry Expert Summit in Boston
-
Can-Fite: Findings Showing the Complete Clearance of Cancer in Patient Treated With Namodenoson Will Be Presented at the AASLD Liver Meeting®
-
Can-Fite to Present its Phase IIb NASH Drug Candidate Namodenoson at Upcoming Conference
-
Can-Fite: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented by KOL Dr. Papp at the 31st European Academy of Dermatology
-
Can-Fite Reports Second Quarter 2022 Financial Results & Provides Clinical Update
-
Can-Fite’s Drug Namodenoson Approved for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania
-
Can-Fite Selected to Present the Positive Psoriasis Phase III Data at the 31st European Academy of Dermatology and Venerology Congress
-
Can-Fite BioPharma (CANF) Reports Progress in the Development of Piclidenoson for Osteoarthritis in Pets Through its Partner Vetbiolix
-
Can-Fite: Reports Progress in the Development of Piclidenoson for Osteoarthritis in Pets Through its Partner Vetbiolix
-
Can-Fite BioPharma (CANF) to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis
-
Can-Fite to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis
-
Can-Fite Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT™ Study in Moderate to Severe Psoriasis
-
Can-Fite’s CF602 Reverses Erectile Dysfunction in Diabetic Pre-clinical Model: Study Published in Peer-Reviewed Journal Andrologia
-
Can-Fite BioPharma (CANF) Announces Publication of Clinical Study Data for Piclidenoson and Namodenoson in Scientific Journal
-
Can-Fite Announces Publication of Clinical Study Data for Piclidenoson and Namodenoson in Scientific Journal
-
Can-Fite Reports First Quarter 2022 Financial Results & Provides Clinical Update
-
Can-Fite Granted Key NASH Patent in Israel
-
Can-Fite’s CEO to Present Namodenoson’s Efficacy in Liver Cancer as Expert Speaker at the Adenosine Pathway Targeted Cancer Immunotherapy Summit
-
Can-Fite is Developing a Topical Piclidenoson Psoriasis Treatment that Shows Efficacy in a Preclinical Model: Potential Complementary Product to its Phase III Oral Psoriasis Drug
-
Can-Fite to Present at Dermatology Drug Development Summit Europe on April 6, 2022
-
Can-Fite BioPharma (CANF) Announces Namodenoson’s Treatment of Liver Fibrosis Receives Notice of Allowance from U.S. Patent Office
-
Can-Fite: Namodenoson’s Treatment of Liver Fibrosis Receives Notice of Allowance from U.S. Patent Office
-
Can-Fite’s Findings in the Treatment of Liver Diseases with Cannabinoids to be Presented at CannX Medical Cannabis Conference in Tel Aviv
-
Can-Fite’s Phase III Psoriasis Study Data Expected Q2 2022
-
Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with Namodenoson
-
Prior to Phase III Psoriasis Data Release Can Fite Reports that Piclidenoson Destroys Pathological Skin Cells in vitro
-
Can-Fite to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference
-
Can-Fite Issues Letter to Shareholders
-
Following Complete Clearance of Cancer Lesions in Advanced Liver Cancer Patient, Can-Fite is Filing Patent Applications for the Treatment of Various Advanced Solid Tumors
-
Can-Fite Announces Exercise of Warrants for Cash Proceeds of $10 Million
-
Can-Fite BioPharma (CANF) Announces Liver Cancer Patient Treated with its Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study
-
Liver Cancer Patient Treated with Can-Fite’s Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study
-
Can-Fite BioPharma (CANF) Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January; Topline Data Expected Q1 2022
-
Can-Fite’s Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January; Topline Data Expected Q1 2022
-
Can-Fite Reports Third Quarter 2021 Financial Results & Provides Clinical Update
-
Can-Fite CEO Dr. Pnina Fishman to be Guest Speaker at 5th Annual NASH Summit 2021
-
Can-Fite’s Piclidenoson Commences Clinical Study for the Treatment of Canine Osteoarthritis
-
Can-Fite to Present at H.C. Wainwright 7th Annual Israel Conference
-
Can-Fite BioPharma (CANF) Findings on Cannabis Compound’s Inhibition of Liver Cancer are Published in HEPATOLOGY and will be Presented at the AASLD
-
Can-Fite’s Findings on Cannabis Compound’s Inhibition of Liver Cancer are Published in HEPATOLOGY and will be Presented at the AASLD’s The Liver Meeting® 2021 Conference
-
Can-Fite BioPharma (CANF) NASH Patents Granted and Allowed in Japan, Hong Kong, and Mexico
-
Can-Fite’s NASH Patents Granted and Allowed in Japan, Hong Kong, and Mexico
-
Can-Fite CEO to Present Namodenoson’s Clinical Trial Data as Expert Speaker at 5th Annual Antifibrotic Drug Development Summit
-
Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal
Back to CFBI Stock Lookup
